2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19210
    SB-209670 157659-79-5 98%
    SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty.
    SB-209670
  • HY-19214
    Elisartan 149968-26-3 98%
    Elisartan is an orally active non-peptide pro-agent of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.
    Elisartan
  • HY-19216
    KR-30450 172489-10-0 98%
    KR-30450 (SKP 450) is a potent K+ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release.
    KR-30450
  • HY-19219
    BMS-189664 162166-80-5 98%
    BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research.
    BMS-189664
  • HY-19274
    ZD-1611 186497-38-1 98%
    ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.
    ZD-1611
  • HY-19367
    MD-39-AM 72564-74-0 98%
    MD-39-AM exhibits antihypertensive, diuretic and saliuretic activities with good in vivo pharmacokinetic characters.
    MD-39-AM
  • HY-19399
    Iroxanadine 276690-58-5 98%
    Iroxanadine (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine has the potential for atherosclerosis and vascular diseases research.
    Iroxanadine
  • HY-19442
    Idrabiotaparinux 774531-07-6 98%
    Idrabiotaparinux, a derivative of Idraparinux (HY-19691), is a novel synthetic anticoagulant that links Idraparinux, a specific, indirect factor Xa inhibitor, to biotin.
    Idrabiotaparinux
  • HY-19660
    Inogatran 155415-08-0 98%
    Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.
    Inogatran
  • HY-19754
    CRA-026440 847460-34-8 98%
    CRA-026440 is a potent, broad-spectrum HDAC inhibitor. The Ki values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4, 14, 11, 15, 7, and 20 nM respectively. CRA-026440 shows antitumor and antiangiogenic activities. CRA-026440 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CRA-026440
  • HY-19866
    Darexaban glucuronide 432029-12-4 98%
    Darexaban glucuronide (YM-222714) is a active metabolite of darexaban (YM150). Darexaban glucuronide has an oral activity and antithrombotic effect.
    Darexaban glucuronide
  • HY-19890
    Aminaftone 14748-94-8 98%
    Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 (ET-1) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.
    Aminaftone
  • HY-19924
    GSK-1440115 1003878-16-7 98%
    GSK-1440115 is an antagonist of the Urotensin II Receptor with an IC50 value of 82.3 nM.
    GSK-1440115
  • HY-43670
    Chlorthalidone impurity 5270-74-6 98%
    Chlorthalidone impurity is a metabolite of Chlorthalidone (HY-15833). Chlorthalidone is a thiazide-like diuretic used to treat hypertension.
    Chlorthalidone impurity
  • HY-50761
    Libenzapril 109214-55-3 98%
    Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibitor. Libenzapril has the potential for ischemia-induced heart failure research.
    Libenzapril
  • HY-69172
    RS-25344 152814-89-6 98%
    RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4). RS-25344 increases intracellular cAMP (cyclic adenosine phosphate) concentration by inhibiting PDE4 activity. RS-25344 can be used in the study of inflammation, immune diseases, neurodegenerative diseases and cardiovascular diseases.
    RS-25344
  • HY-76520
    Sitaxsentan 184036-34-8 98%
    Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist.
    Sitaxsentan
  • HY-A0113
    Cilazaprilat 90139-06-3 98%
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-A0114
    Moexiprilat 103775-14-0 98%
    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.
    Moexiprilat
  • HY-A0117
    Temocaprilat 110221-53-9 98%
    Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation.
    Temocaprilat
Cat. No. Product Name / Synonyms Application Reactivity